The acquisition positions the company with a suite of AI-powered breast cancer image interpretation and workflow solutions.
RadNet Inc announced that its wholly owned subsidiary DeepHealth has completed the acquisition of iCAD Inc, specializing in AI-powered breast health solutions. The integration of iCAD’s complementary commercial, technology, and regulatory capabilities into DeepHealth advances its aim to address clinical and operational challenges in screening and diagnosis by harnessing the power of AI and imaging.
“The integration of iCAD further empowers DeepHealth to meet the real-world clinical needs of today, from improving the accuracy and early detection of breast cancer to orchestrating large-scale screening programs, while shaping the future of breast cancer management,” says Kees Wesdorp, president and CEO of RadNet’s digital health segment, in a release. “Our combined capabilities position us for accelerated growth and rapid delivery of transformative, AI-powered population health solutions.”
iCAD’s AI portfolio—including breast cancer detection, risk evaluation, breast density, and breast arterial calcification assessment—is deployed in more than 50 countries. This portfolio will be integrated with DeepHealth’s end-to-end screening and diagnostic solutions.
With expanded market access through iCAD’s installed base of over 1,500 healthcare provider locations worldwide, this acquisition enables DeepHealth to scale its impact to over 10 million mammograms annually, according to a release from the company. This global reach aims to accelerate AI adoption and screening compliance by bringing AI-powered solutions to communities around the world, including those that are underserved.
ID 155234616 | Ai Medical © thanakorn hormniam | Dreamstime.com
